Dilated cardiomyopathy revealing Refsum disease: a case report.
Dilated cardiomyopathy
Phytanic acid
Refsum disease
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
30 Sep 2024
30 Sep 2024
Historique:
received:
30
07
2024
accepted:
28
08
2024
medline:
30
9
2024
pubmed:
30
9
2024
entrez:
29
9
2024
Statut:
epublish
Résumé
Refsum disease is a rare autosomal recessive hereditary disorder of lipid metabolism that results in the accumulation of phytanic acid. This syndrome is characterized with a range of classic symptoms including ataxia, peripheral neuropathy, amyotrophy, retinopathy, ichthyosis, and hearing loss. Later in life, individuals with Refsum disease may present cardiac manifestations, such as arrhythmias or conduction defects (first-degree atrioventricular block and bundle branch block) and hypertrophic or dilated cardiomyopathy, leading to heart failure and sudden death. To the best of our knowledge, this is the first case revealed by cardiac manifestations described in literature. We report the case of 38-year-old white Moroccan male who was admitted in our department for an acute decompensated heart failure episode. Transthoracic echocardiography found a dilated cardiomyopathy with a reduced ejection fraction at 15%. Further evaluation showed different features of Refsum disease. High plasma level of phytanic acid confirmed the diagnosis. Cardiac manifestations are frequent in the late course of the adult Refsum disease and include, cardiomyopathy, electrical abnormalities, and sudden cardiac death. Moreover, arrhythmias remain one of the main causes of death in these patients. Refsum's disease is an autosomal recessive disorder. It presents as retinitis pigmentosa with anosmia, deafness ataxia, and cardiac defects. Current interventions for individuals with Refsum disease consist of dietary phytanic acid restriction and lipid apheresis to control symptoms and enhance quality of life.
Sections du résumé
BACKGROUND
BACKGROUND
Refsum disease is a rare autosomal recessive hereditary disorder of lipid metabolism that results in the accumulation of phytanic acid. This syndrome is characterized with a range of classic symptoms including ataxia, peripheral neuropathy, amyotrophy, retinopathy, ichthyosis, and hearing loss. Later in life, individuals with Refsum disease may present cardiac manifestations, such as arrhythmias or conduction defects (first-degree atrioventricular block and bundle branch block) and hypertrophic or dilated cardiomyopathy, leading to heart failure and sudden death. To the best of our knowledge, this is the first case revealed by cardiac manifestations described in literature.
CASE PRESENTATION
METHODS
We report the case of 38-year-old white Moroccan male who was admitted in our department for an acute decompensated heart failure episode. Transthoracic echocardiography found a dilated cardiomyopathy with a reduced ejection fraction at 15%. Further evaluation showed different features of Refsum disease. High plasma level of phytanic acid confirmed the diagnosis. Cardiac manifestations are frequent in the late course of the adult Refsum disease and include, cardiomyopathy, electrical abnormalities, and sudden cardiac death. Moreover, arrhythmias remain one of the main causes of death in these patients.
CONCLUSION
CONCLUSIONS
Refsum's disease is an autosomal recessive disorder. It presents as retinitis pigmentosa with anosmia, deafness ataxia, and cardiac defects. Current interventions for individuals with Refsum disease consist of dietary phytanic acid restriction and lipid apheresis to control symptoms and enhance quality of life.
Identifiants
pubmed: 39343965
doi: 10.1186/s13256-024-04789-5
pii: 10.1186/s13256-024-04789-5
doi:
Substances chimiques
Phytanic Acid
14721-66-5
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
470Informations de copyright
© 2024. The Author(s).
Références
Rossi M, Wainsztein N, Merello M. Cardiac involvement in movement disorders. Mov Disord Clin Practice. 2021;8(5):651–68.
doi: 10.1002/mdc3.13188
Wills AJ, Manning NJ, Reilly MM. Refsum’s disease. QJM. 2001;94(8):403–6.
doi: 10.1093/qjmed/94.8.403
pubmed: 11493716
Kumar R, De Jesus O. Refsum disease. In: Kumar R, De Jesus O, editors. StatPearls. St. Petersburg: StatPearls Publishing; 2022.
Mihalik SJ, Morrell JC, Kim DO, Sacksteder KA, Watkins PA, Gould SJ. Identification of PAHX, a Refsum disease gene. Nat Genet. 1997;17(2):185–9.
doi: 10.1038/ng1097-185
pubmed: 9326939
Van Den Brink DM, Brites P, Haasjes J, Wierzbicki AS, Mitchell J, Lambert-Hamill M, et al. Identification of PEX7 as the second gene involved in Refsum disease. Am J Human Genetics. 2003;72(2):471–7.
doi: 10.1086/346093
Hansen KP. 3, 7, 11, 15-tetramethylhexadecanoic acid: its occurrence in the tissues of humans afflicted with Refsum’s syndrome. Biochimica Et Biophysica Acta BBA Lipid Lipid Metab. 1965;106(2):304–10.
doi: 10.1016/0005-2760(65)90038-X
Claridge KG, Gibberd FB, Sidey MC. Refsum disease: the presentation and ophthalmic aspects of Refsum disease in a series of 23 patients. Eye. 1992;6(4):371–5.
doi: 10.1038/eye.1992.76
pubmed: 1282471
Gibberd FB, Feher MD, Sidey MC, Wierzbicki AS. Smell testing: an additional tool for identification of adult Refsum’s disease. J Neurol Neurosurg Psychiatry. 2004;75(9):1334–6.
doi: 10.1136/jnnp.2003.026690
pubmed: 15314127
pmcid: 1739246
Bamiou DE, Spraggs PRD, Gibberd FB, Sidey MC, Luxon LM. Hearing loss in adult Refsum’s disease. Clin Otolaryngol Allied Sci. 2003;28(3):227–30.
doi: 10.1046/j.1365-2273.2003.00694.x
pubmed: 12755761
Leys D, Petit H, Bonte-Adnet C, Millaire A, Fourrier F, Dubois F, et al. Refsum’s disease revealed by cardiac disorders. The Lancet. 1989;333(8638):621.
doi: 10.1016/S0140-6736(89)91654-1
Waterham HR, Wanders RJ, Leroy BP. Adult Refsum disease. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301527.
Rüether K, Baldwin E, Casteels M, Feher MD, Horn M, Kuranoff S, et al. Adult Refsum disease: a form of tapetoretinal dystrophy accessible to therapy. Surv Ophthalmol. 2010;55(6):531–8.
doi: 10.1016/j.survophthal.2010.03.007
pubmed: 20850855
Li JJ, Kim JJ, Nausheen F. Phytanic acid intake and lifestyle modifications on quality of life in individuals with adult Refsum disease: a retrospective survey analysis. Nutrients. 2023;15(11):2551. https://doi.org/10.3390/nu15112551 .
doi: 10.3390/nu15112551
pubmed: 37299514
pmcid: 10255135
Wanders RJA, Jansen GA, Skjeldal OH. Refsum disease, peroxisomes and phytanic acid oxidation a review. J Neuropathol Exp Neurol. 2001;60(11):1021–31. https://doi.org/10.1093/jnen/60.11.1021 .
doi: 10.1093/jnen/60.11.1021
pubmed: 11706932
Panteliadis CP, Hagel C. Refsum disease (heredopathia atactica polyneuritiformis). In: Panteliadis CP, Benjamin R, Hagel C, editors. Neurocutaneous disorders. Cham: Springer; 2022.
doi: 10.1007/978-3-030-87893-1
Matsunami M, Shimozawa N, Fukuda A, Kumagai T, Kubota M, Chong PF, Kasahara M. Living-donor liver transplantation from a heterozygous parent for infantile Refsum disease. Pediatrics. 2016;137(6):e20153102. https://doi.org/10.1542/peds.2015-3102 .
doi: 10.1542/peds.2015-3102
pubmed: 27221287
Wills AJ, Manning NJ, Reilly MM. Refsum’s disease. QJM Int J Med. 2001;94(8):403–6. https://doi.org/10.1093/qjmed/94.8.403 .
doi: 10.1093/qjmed/94.8.403